We've found
9,144
archived clinical trials in
Ocular
We've found
9,144
archived clinical trials in
Ocular
Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)
Immune Ablation and Hematopoietic Stem Cell Transplantation in Patients With Autoimmune-Related Retinopathy and Optic Neuropathy (ARRON) Syndrome (Not Associated With Cancer)
Status: Archived
Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)
Updated: 1/1/1970
Immune Ablation and Hematopoietic Stem Cell Transplantation in Patients With Autoimmune-Related Retinopathy and Optic Neuropathy (ARRON) Syndrome (Not Associated With Cancer)
Status: Archived
Updated: 1/1/1970
Autoimmune Dysregulation in Pigmentary Glaucoma
Autoimmune Dysregulation in Pigmentary Glaucoma
Status: Archived
Autoimmune Dysregulation in Pigmentary Glaucoma
Updated: 1/1/1970
Autoimmune Dysregulation in Pigmentary Glaucoma
Status: Archived
Updated: 1/1/1970
Phacoemulsification Sleeves
Determination of Surgical Efficacy and Most Efficient Surgical Parameters for Use With the 2.2, 2.8, and 3.0mm Phacoemulsification Sleeves Used With the Alcon Infinity 1.1mm ABS Flared Tip
Status: Archived
Phacoemulsification Sleeves
Updated: 1/1/1970
Determination of Surgical Efficacy and Most Efficient Surgical Parameters for Use With the 2.2, 2.8, and 3.0mm Phacoemulsification Sleeves Used With the Alcon Infinity 1.1mm ABS Flared Tip
Status: Archived
Updated: 1/1/1970
Tracking Optical Coherence Tomography
Updated: 1/1/1970
Tracking Optical Coherence Tomography
Status: Archived
Updated: 1/1/1970
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
Status: Archived
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
Updated: 1/1/1970
Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.
Status: Archived
Updated: 1/1/1970
One Hour Preoperative Gatifloxacin
Updated: 1/1/1970
One Hour Preoperative Gatifloxacin
Status: Archived
Updated: 1/1/1970
Intra Ocular Pressure During Robotic Prostatectomy
Intra Ocular Pressure During Robotic Prostatectomy
Status: Archived
Intra Ocular Pressure During Robotic Prostatectomy
Updated: 1/1/1970
Intra Ocular Pressure During Robotic Prostatectomy
Status: Archived
Updated: 1/1/1970
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine
Status: Archived
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Updated: 1/1/1970
A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine
Status: Archived
Updated: 1/1/1970
To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series
To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series With Respect to Reliability, Reproducibility, Test Duration, Patient Preference, Technician Preference.
Status: Archived
To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series
Updated: 1/1/1970
To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series With Respect to Reliability, Reproducibility, Test Duration, Patient Preference, Technician Preference.
Status: Archived
Updated: 1/1/1970
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Identification of Key Blood Molecular Markers for Immunotherapy
Updated: 1/1/1970
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Updated: 1/1/1970
A Multi-Center Study of Reading Rehabilitation in Macular Disease
A Multi-Center Study of Reading Rehabilitation in Macular Disease
Status: Archived
A Multi-Center Study of Reading Rehabilitation in Macular Disease
Updated: 1/1/1970
A Multi-Center Study of Reading Rehabilitation in Macular Disease
Status: Archived
Updated: 1/1/1970
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
Updated: 1/1/1970
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Updated: 1/1/1970
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
Updated: 1/1/1970
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Updated: 1/1/1970
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
Updated: 1/1/1970
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Updated: 1/1/1970
Pegaptanib Therapy in Uveitis
Evaluation of the Utility of Intravitreal Vascular Endothelial Growth Factor (VEGF) Blockade With Pegaptanib in Cystoid Macular Edema (CME) Associated With Non Infectious Intermediate and Panuveitis in an Open Label, Non Randomized, Uncontrolled Interventional Pilot Trial.
Status: Archived
Pegaptanib Therapy in Uveitis
Updated: 1/1/1970
Evaluation of the Utility of Intravitreal Vascular Endothelial Growth Factor (VEGF) Blockade With Pegaptanib in Cystoid Macular Edema (CME) Associated With Non Infectious Intermediate and Panuveitis in an Open Label, Non Randomized, Uncontrolled Interventional Pilot Trial.
Status: Archived
Updated: 1/1/1970
Partnership for Rapid Elimination of Trachoma
Research to Programs for Trachoma Elimination: Antibiotic Trial
Status: Archived
Partnership for Rapid Elimination of Trachoma
Updated: 1/1/1970
Research to Programs for Trachoma Elimination: Antibiotic Trial
Status: Archived
Updated: 1/1/1970
Partnership for Rapid Elimination of Trachoma
Research to Programs for Trachoma Elimination: Antibiotic Trial
Status: Archived
Partnership for Rapid Elimination of Trachoma
Updated: 1/1/1970
Research to Programs for Trachoma Elimination: Antibiotic Trial
Status: Archived
Updated: 1/1/1970
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®
Status: Archived
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
Updated: 1/1/1970
An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®
Status: Archived
Updated: 1/1/1970
Ciracadian Ocular Perfusion and Ocular Blood Flow
Status: Archived
Ciracadian Ocular Perfusion and Ocular Blood Flow
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970
Kynex Versus Refresh Plus Study in Subject With Dry Eye
The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study
Status: Archived
Kynex Versus Refresh Plus Study in Subject With Dry Eye
Updated: 1/1/1970
The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study
Status: Archived
Updated: 1/1/1970
Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery
Effect of Perioperative Intravenous Lidocaine Administration or Epidural Anesthesia on Postoperative Outcomes in Complex Spine Surgery
Status: Archived
Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery
Updated: 1/1/1970
Effect of Perioperative Intravenous Lidocaine Administration or Epidural Anesthesia on Postoperative Outcomes in Complex Spine Surgery
Status: Archived
Updated: 1/1/1970
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids
Status: Archived
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Updated: 1/1/1970
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids
Status: Archived
Updated: 1/1/1970
Study of T-PRED(TM) Compared to Pred Forte(R) II
Status: Archived
Study of T-PRED(TM) Compared to Pred Forte(R) II
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970
Travoprost 0.004%/Timolol 0.5% Versus Timolol 0.5% in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Status: Archived
Travoprost 0.004%/Timolol 0.5% Versus Timolol 0.5% in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females
Status: Archived
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
Updated: 1/1/1970
A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females
Status: Archived
Updated: 1/1/1970
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females
Status: Archived
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
Updated: 1/1/1970
A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females
Status: Archived
Updated: 1/1/1970
Apremilast in the Treatment of Uveitis
An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.
Status: Archived
Apremilast in the Treatment of Uveitis
Updated: 1/1/1970
An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.
Status: Archived
Updated: 1/1/1970
Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms
Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy
Status: Archived
Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms
Updated: 1/1/1970
Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy
Status: Archived
Updated: 1/1/1970
Effect of Different Concentrations of 1334H on Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the of 1334H 0.15%, 0.3%, and 0.45% Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Archived
Effect of Different Concentrations of 1334H on Allergic Conjunctivitis
Updated: 1/1/1970
A Multi-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the of 1334H 0.15%, 0.3%, and 0.45% Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Archived
Updated: 1/1/1970
SENSIMED Triggerfish Safety and Tolerability
Evaluation of SENSIMED Triggerfish Safety and Tolerability in Glaucoma Patients and Glaucoma Suspects
Status: Archived
SENSIMED Triggerfish Safety and Tolerability
Updated: 1/1/1970
Evaluation of SENSIMED Triggerfish Safety and Tolerability in Glaucoma Patients and Glaucoma Suspects
Status: Archived
Updated: 1/1/1970
AL-54478 Proof of Concept Study
Status: Archived
AL-54478 Proof of Concept Study
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970
Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C
Status: Archived
Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
Status: Archived
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
Updated: 1/1/1970
Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
Status: Archived
Updated: 1/1/1970
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery
Status: Archived
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Updated: 1/1/1970
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
AR-12286 in Combination With Latanoprost
Updated: 1/1/1970
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Status: Archived
Updated: 1/1/1970
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt
Status: Archived
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
Updated: 1/1/1970
Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt
Status: Archived
Updated: 1/1/1970
A Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses
A Randomized, Pilot Study, Subject Masked Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses (IOLs)
Status: Archived
A Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses
Updated: 1/1/1970
A Randomized, Pilot Study, Subject Masked Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses (IOLs)
Status: Archived
Updated: 1/1/1970
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Status: Archived
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Updated: 1/1/1970
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Status: Archived
Updated: 1/1/1970
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Status: Archived
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Updated: 1/1/1970
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
Status: Archived
Updated: 1/1/1970
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
Status: Archived
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
Updated: 1/1/1970
The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
Status: Archived
Updated: 1/1/1970
Divided Dose of Travatan
Status: Archived
Divided Dose of Travatan
Status: Archived
Updated: 1/1/1970
Updated: 1/1/1970